Recent patenting activities in the discovery and development of vasopressin V₂ receptor agonists

Bibliography

• Hardman JG, Limbird LE. Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw- Hill, New York; 2001. p. 789
   Google Scholar
• Guyton AC, Hall JE. Textbook of medical physiology. 9th edition. W.B. Saunders, Medina; 1999. p. 933
   Google Scholar
• Michel RH, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 1979;7:861
   PubMedGoogle Scholar
• Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest 1985;76:1857
   PubMed Web of Science ®Google Scholar
• Laszlo FA, Laszlo F, De Weid D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991;43:73
   PubMed Web of Science ®Google Scholar
• Bouby N, Bachmann S, Bichet D, Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990;258:F973
   PubMed Web of Science ®Google Scholar
• Preston GM, Carroll TP, Guggino WB, Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science 1992;256:385
   PubMed Web of Science ®Google Scholar
• Fushimi K, Uchida S, Hara Y, Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549
   PubMed Web of Science ®Google Scholar
• Kondo K. Recent discovery and development of non-peptide vasopressin V2 receptor agonists. Expert Opin Ther Patents 2002;12(8):1249
   Web of Science ®Google Scholar
• Otsuka Pharmaceutical Co., Ltd. Benzazepin derivatives with vasopressin agonistic activity. WO9722591; 1997
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. Amide derivatives. JP11001456; 1999
   Google Scholar
• Kondo K, Ogawa H, Shinohara T, Novel design of nonpeptide AVP V2 receptor agonists: structural requirements for an agonist having 1-(4- aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template. J Med Chem 2000;43:4388
   PubMed Web of Science ®Google Scholar
• Kondo K, Kan K, Tanada Y, Characterization of orally active nonpeptide vasopressin V2 receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide. J Med Chem 2002;45:3805
   PubMed Web of Science ®Google Scholar
• Emory University. Nonpeptide agonists and antagonists of vasopressin receptors. WO002047679; 2002
   Google Scholar
• Weyth. N-biphenylcarbonyl- and N-phenylpyridylcarbonyl substituted bi- and tricyclicazepines as vasopressin agonists. WO02083145; 2002
   Google Scholar
• Wyeth. Cyclohexylphenyl vasopressin agonists. WO02083685; 2002
   Google Scholar
• Wyeth. Pyrrolo[2,1-c][1,4]benzodiazepines as vasopressin agonists. WO2004060894; 2004
   Google Scholar
• Venkatesan AM, Grosu GT, Failli AA, (4-Substituted-phenyl)-(5H-10,11- dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators. Bioorg Med Chem Lett 2005;15:5003
   PubMed Web of Science ®Google Scholar
• Failli AA, Shumsky JS, Steffan RJ, Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett 2006;16:954
   PubMed Web of Science ®Google Scholar
• Yamanouchi Pharmaceutical Co., Ltd. 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof. WO2003042181; 2003
   Google Scholar
• Yamanouchi Pharmaceutical Co., Ltd. 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof. WO2004096775; 2004
   Google Scholar
• Tsukamoto I, Koshio H, Akamatsu S, Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists. Bioorg Med Chem 2008;16:9524
   PubMed Web of Science ®Google Scholar
• Tsukamoto I, Koshio H, Kuramochi T, Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists. Bioorg Med Chem 2009;17:3130
   PubMed Web of Science ®Google Scholar
• Tsukamoto I, Koshio H, Orita M, Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene) acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes. Bioorg Med Chem 2009;17:8161
   PubMed Web of Science ®Google Scholar
• Ferring BV. Heterocyclic condensed compounds useful as antidiuretic agents. WO2006018443; 2006
   Google Scholar
• Yea CM, Allan CE, Ashworth DM, New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem 2008;51:8124
   PubMed Web of Science ®Google Scholar
• Kissei Pharmaceutical Co., Ltd. Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both. WO2006054560; 2006
   Google Scholar
• Kissei Pharmaceutical Co., Ltd. Urea derivative, medicinal composition containing the same, and medicinal use of these. WO2006104008; 2006
   Google Scholar
• Kissei Pharmaceutical Co., Ltd. 1,4-Benzodiazepine derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes. WO2008038600; 2008
   Google Scholar
• Dimson SB. Desmopressin as a treatment for enuresis. Lancet 1977;1:1260
   PubMed Web of Science ®Google Scholar
• Ferring International Center SA. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia. WO2009143356; 2009
   Google Scholar
• Ferring BV. A fast dissolving pharmaceutical composition. WO2011120904; 2011
   Google Scholar
• Ferring International Center SA. Desmopressin for reducing nocturnal voids. WO2012001469; 2012
   Google Scholar
• Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin. US7405203; 2007
   Google Scholar
• Takei M. Hainyou-shougai. Practice 2005;13(1):59; written in Japanese
   Google Scholar
• Kelleher H, Henderson S. Severe hyponatremia due to desmopressin. J Emerg Med 2006;30:45
   PubMed Web of Science ®Google Scholar
• Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis 2010;21(7):615
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167
   PubMed Web of Science ®Google Scholar
• Schatzl G, Temml C, Schmidbauer J, Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology 2000;56:71
   PubMed Web of Science ®Google Scholar
• Asplund R. Nocturia, nocturnal polyuria, and sleep quality in the elderly. J Psychosom Res 2004;56(5):517
   PubMed Web of Science ®Google Scholar
• McKeigue PM, Reynard JM. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet 2000;355(9202):486
   PubMed Web of Science ®Google Scholar
• Hirayama A, Fujimoto K, Matsumoto Y, Nocturia in men with lower urinary tract symptoms is associated with both nocturnal polyuria and detrusor overactivity with positive response to ice water test. Urology 2005;65:1064
   PubMed Web of Science ®Google Scholar
• Robben JH, Kortenoeven ML, Sze M, Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009;106(29):12195
   PubMed Web of Science ®Google Scholar